Aditxt, Inc. 8-K

What Happened Aditxt, Inc. (ADTX) filed an 8-K on June 24, 2026 reporting that the Nasdaq Hearings Panel denied the company’s request to continue its Nasdaq listing. Nasdaq staff had initially notified Aditxt on May 6, 2026 that its share price closed below $1.00 for 30 consecutive business days (March 24–May 5, 2026) and was not eligible for the usual 180-day cure period because of prior reverse stock splits. On May 27, 2026 Nasdaq also notified the company that its reported stockholders’ equity of $(35,174,386) (Form 10-Q for period ended March 31, 2026) failed to meet the $2,500,000 minimum for continued listing. A hearing was held June 11, 2026 and the Panel issued a Notice on June 23, 2026 denying continued listing; trading on Nasdaq will be suspended at the open on June 25, 2026.

Key Details

• Bid price deficiency: share price closed under $1.00 for 30 consecutive business days (March 24–May 5, 2026), violating Nasdaq Rule 5550(a)(2).
• Reverse splits: Nasdaq cited prior reverse stock splits (cumulative ratio of 250:1 over two years) making the company ineligible for a 180-day cure period under Rule 5810(c)(3)(A)(iv).
• Equity deficiency: reported stockholders’ equity of $(35,174,386) (Q1 2026) fails Nasdaq’s $2,500,000 requirement under Rule 5550(b)(1).
• Procedural status: A hearing occurred June 11; Panel denied continued listing on June 23. Aditxt may seek review by the Nasdaq Listing and Hearing Review Council within 15 days of receiving the Notice.

Why It Matters This 8-K reports a confirmed Nasdaq suspension decision, which will halt trading of Aditxt’s common stock on Nasdaq at the open on June 25, 2026. For shareholders, suspension reduces liquidity and may limit where and how the stock can be traded. The company has a limited procedural option to request further review within 15 days, but the Panel’s decision is currently final per this filing. The 8-K also includes the Panel’s Notice and states customary forward-looking statement cautions.